These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 21257151)
1. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. Shimura M; Yasuda K; Miyazawa A; Otani T; Nakazawa T Am J Ophthalmol; 2011 Apr; 151(4):697-702.e2. PubMed ID: 21257151 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis. Kamis U; Ozturk BT; Ozkagnici A; Gunduz K Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458 [No Abstract] [Full Text] [Related]
3. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis]. Endre L; Hidasi V Orv Hetil; 2006 Sep; 147(36):1741-3. PubMed ID: 17087018 [TBL] [Abstract][Full Text] [Related]
4. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Leonardi A; Quintieri L Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Avunduk AM; Tekelioglu Y; Turk A; Akyol N Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412 [TBL] [Abstract][Full Text] [Related]
8. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Villareal AL; Farley W; Pflugfelder SC Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387 [TBL] [Abstract][Full Text] [Related]
10. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867 [TBL] [Abstract][Full Text] [Related]
11. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Abelson MB; Gomes PJ Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):453-61. PubMed ID: 18433347 [TBL] [Abstract][Full Text] [Related]
12. Olopatadine for allergic conjunctivitis. Med Lett Drugs Ther; 1997 Nov; 39(1014):108-9. PubMed ID: 9398823 [No Abstract] [Full Text] [Related]
13. [Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis]. Turlea M; Mârza F; Turlea C Oftalmologia; 2009; 53(4):67-71. PubMed ID: 20361653 [TBL] [Abstract][Full Text] [Related]
14. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Greiner JV; Udell IJ Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305 [TBL] [Abstract][Full Text] [Related]
15. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Leonardi A; Abelson MB Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Abelson MB; Greiner JV Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212 [TBL] [Abstract][Full Text] [Related]
17. Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans. Shindo M; Yoshida Y; Yamamoto O Pharmacology; 2011; 87(3-4):152-4. PubMed ID: 21346393 [TBL] [Abstract][Full Text] [Related]
18. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089 [TBL] [Abstract][Full Text] [Related]
19. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Aguilar AJ Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352 [TBL] [Abstract][Full Text] [Related]
20. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]